Treating sarcopenic obesity in the era of incretin therapies: perspectives and challenges
Open accessAbstract
Sarcopenic obesity, a subtype of obesity, is marked by reduced skeletal muscle mass and function, or sarcopenia, and poses a significant health challenge to older adults as it affects an estimated 28.3% of people aged >60 years. This subtype is unique to older adults as aging exacerbates sarcopenia and obesity due to changes in energy metabolism, hormones and inflammatory markers, and lifestyle factors. Traditional treatments for sarcopenic obesity have been focused on exercise and dietary modifications to reduce fat while maintaining muscle mass. Newer glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dual gastric inhibitory polypeptide/GLP-1 receptor agonists (GIP/GLP-1RAs), including liraglutide, semaglutide, and tirzepatide, have shown great promise to reduce weight, treat obesity-related complications, improve physical function, and improve quality of life, in younger clinical trial populations. However, the use of GLP-1RAs and GIP/GLP-1RAs has not been exhaustively evaluated in older adults with sarcopenic obesity. These medications come with the risk of loss of muscle mass and an increased rate of adverse events. Thus, clinicians should use them cautiously by weighing the potential benefits against their risks. Herein, we discuss a possible approach to using GLP-1RAs and GIP/GLP-1RAs in patients with sarcopenic obesity, including considerations for patient identification, monitoring, maintenance, and discontinuation. In this article we also discuss the emerging treatments that will be available, which may include activin type II receptor antibodies and selective androgen receptor agonists. We conclude by highlighting the advancement of geroscience as a promising field for individualizing treatments in the future. Article Highlights: Sarcopenic obesity, reduced muscle mass and strength coupled with obesity, poses significant health risks to older adults. Aging exacerbates sarcopenia and obesity due to metabolic, hormonal, inflammatory, and lifestyle changes. Traditional interventions emphasize exercise and diet to reduce fat mass while preserving muscle mass. Incretin therapies show promise in weight reduction and physical improvement in younger populations but are minimally studied in older adults. These medications can be used to treat several obesity-related complications, which older adults with sarcopenic obesity are prone to developing. These medications need to be used cautiously among older adults, considering potential muscle mass loss and adverse events.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Older people with sarcopenia before starting incretin-based treatment could be at particular risk of critical reduction in muscle mass and functional impairments.
“Older people with sarcopenia before starting such treatment could be at particular risk.95”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [95]
Strength training and other strategies to preserve lean body mass are likely particularly important in patients using anti-obesity medications and in older adults who may have sarcopenic obesity.
“Strength training and other strategies to preserve lean body mass are likely to be particularly important in patients using AOMs, as well as in older adults who may have SO [121,122].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [122]
Balance and mobility training, particularly strength training, is suggested for patients using anti-obesity medications.
“Furthermore, balance and mobility training, particularly strength training [122], is suggested for patients using AOMs [136].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [122]
Physical activity and exercise are the most sustainable strategy to counteract sarcopenic obesity and the lean mass loss caused by anti-obesity medications.
“Moreover, they are the most sustainable strategy to counteract SO and the LM loss caused by AOMSs [121,122].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · see citing works
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · see citing works
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · see citing works
Physical Activity and Public Health in Older Adults
Nelson, M. E., Rejeski, W. J., Blair, S. N., Duncan, P. W., Judge, J. O., King, A. C., Macera, C. A., & Castaneda‐Sceppa, C. (2007) · Circulation · doi:10.1161/circulationaha.107.185650 · Cited by 2,991 · see citing works
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · see citing works
Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity
Ward, Z. J., Bleich, S. N., Cradock, A. L., Barrett, J. L., Giles, C. M., Flax, C., Long, M. W., & Gortmaker, S. L. (2019) · New England Journal of Medicine · doi:10.1056/nejmsa1909301 · Cited by 2,009 · see citing works
Mechanisms, Pathophysiology, and Management of Obesity
Heymsfield, S. B., & Wadden, T. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1514009 · Cited by 1,867 · see citing works
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669 · see citing works
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · see citing works
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382 · see citing works
Self-citationDent, E., Morley, J. E., Cruz-Jentoft, A. J., Arai, H., Kritchevsky, S. B., Guralnik, J., Bauer, J. M., Pahor, M., Clark, B. C., Cesari, M., et al. (2018) · The Journal of nutrition, health and aging · doi:10.1007/s12603-018-1139-9 · Cited by 1,130 · see citing works
Weight loss, exercise, or both and physical function in obese older adults
Villareal, D. T., Chode, S., Parimi, N., Sinacore, D. R., Hilton, T., Armamento-Villareal, R., Napoli, N., Qualls, C., & Shah, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008234 · Cited by 1,096 · see citing works
Hambrecht, R., Adams, V., Erbs, S., Linke, A. H.-P., Kränkel, N., Shu, Y., Baither, Y., Gielen, S., Thiele, H., Gummert, J. F., et al. (2003) · Circulation · doi:10.1161/01.cir.0000074229.93804.5c · Cited by 941 · see citing works
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404881 · Cited by 871 · see citing works
Flegal, K. M., Shepherd, J. A., Looker, A. C., Graubard, B. I., Borrud, L. G., Ogden, C. L., Harris, T. B., Everhart, J. E., & Schenker, N. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26847 · Cited by 819 · see citing works
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313917 · Cited by 758 · see citing works
Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2021.11.014 · Cited by 566 · see citing works
Self-citationHealthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028198 · Cited by 536 · see citing works
Exercise-induced increase in muscle insulin sensitivity
Holloszy, J. O. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00123.2005 · Cited by 494 · see citing works
Giskes, K., van Lenthe, F. J., Avendano‐Pabon, M., & Brug, J. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00769.x · Cited by 479 · see citing works
Rosenbaum, M., Hirsch, J., Gallagher, D. A., & Leibel, R. L. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/88.4.906 · Cited by 444 · see citing works
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Bliddal, H., Bays, H., Czernichow, S., Uddén Hemmingsson, J., Hjelmesæth, J., Hoffmann Morville, T., Koroleva, A., Skov Neergaard, J., Vélez Sánchez, P., Wharton, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403664 · Cited by 440 · see citing works
Muscle protein synthesis in response to nutrition and exercise
Atherton, P. J., & Smith, K. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2011.225003 · Cited by 401 · see citing works
Sarcopenic obesity in older adults: a clinical overview
Prado, C. M., Batsis, J. A., Donini, L. M., Gonzalez, M. C., & Siervo, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00943-z · Cited by 355 · see citing works
Self-citationKeadle, S. K., McKinnon, R., Graubard, B. I., & Troiano, R. P. (2016) · Preventive Medicine · doi:10.1016/j.ypmed.2016.05.009 · Cited by 351 · see citing works
Heymsfield, S. B., Gonzalez, M. C. C., Shen, W., Redman, L., & Thomas, D. (2014) · Obesity Reviews · doi:10.1111/obr.12143 · Cited by 350 · see citing works
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Ryan, D. H., Lingvay, I., Deanfield, J., Kahn, S. E., Barros, E., Burguera, B., Colhoun, H. M., Cercato, C., Dicker, D., Horn, D. B., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02996-7 · Cited by 347 · see citing works
Heymsfield, S. B., Coleman, L. A., Miller, R., Rooks, D. S., Laurent, D., Petricoul, O., Praestgaard, J., Swan, T., Wade, T., Perry, R. G., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.33457 · Cited by 338 · see citing works
Batsis, J. A., Barre, L. K., Mackenzie, T. A., Pratt, S. I., Lopez‐Jimenez, F., & Bartels, S. J. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12260 · Cited by 330 · see citing works
Self-citationThe regulation of muscle mass by endogenous glucocorticoids
Braun, T. P., & Marks, D. L. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00012 · Cited by 273 · see citing works
Hsu, K.-J., Liao, C.-D., Tsai, M.-W., & Chen, C.-N. (2019) · Nutrients · doi:10.3390/nu11092163 · Cited by 258 · see citing works
Nutrition and Sarcopenia: A Review of the Evidence and Implications for Preventive Strategies
Robinson, S., Cooper, C., & Aihie Sayer, A. (2012) · Journal of Aging Research · doi:10.1155/2012/510801 · Cited by 256 · see citing works
Kim, J. E., O’Connor, L. E., Sands, L. P., Slebodnik, M. B., & Campbell, W. W. (2016) · Nutrition Reviews · doi:10.1093/nutrit/nuv065 · Cited by 238 · see citing works
Appetite after weight loss by energy restriction and a low-fat diet–exercise follow-up
Doucet, E., Imbeault, P., St-Pierre, S., Alméras, N., Mauriège, P., Richard, D., & Tremblay, A. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801251 · Cited by 236 · see citing works
Wharton, S., Calanna, S., Davies, M., Dicker, D., Goldman, B., Lingvay, I., Mosenzon, O., Rubino, D. M., Thomsen, M., Wadden, T. A., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14551 · Cited by 200 · see citing works
Sarcopenic obesity and endocrinal adaptation with age
Sakuma, K., & Yamaguchi, A. (2013) · International Journal of Endocrinology · doi:10.1155/2013/204164 · Cited by 189 · see citing works
Batsis, J. A., Gill, L. E., Masutani, R. K., Adachi‐Mejia, A. M., Blunt, H. B., Bagley, P. J., Lopez‐Jimenez, F., & Bartels, S. J. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14514 · Cited by 160 · see citing works
Self-citationNew Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Jastreboff, A. M., & Kushner, R. F. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-014919 · Cited by 158 · see citing works
Shi, Q., Wang, Y., Hao, Q., Vandvik, P. O., Guyatt, G., Li, J., Chen, Z., Xu, S., Shen, Y., Ge, L., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00351-9 · Cited by 155 · see citing works
Locatelli, J. C., Costa, J. G., Haynes, A., Naylor, L. H., Fegan, P. G., Yeap, B. B., & Green, D. J. (2024) · Diabetes Care · doi:10.2337/dci23-0100 · Cited by 152 · see citing works
Timmerman, K. L., Dhanani, S., Glynn, E. L., Fry, C. S., Drummond, M. J., Jennings, K., Rasmussen, B. B., & Volpi, E. (2012) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.020800 · Cited by 138 · see citing works
Chomentowski, P., Dube, J. J., Amati, F., Stefanovic-Racic, M., Zhu, S., Toledo, F. G. S., & Goodpaster, B. H. (2009) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glp007 · Cited by 137 · see citing works
Nutritional considerations with antiobesity medications
Almandoz, J. P., Wadden, T. A., Tewksbury, C., Apovian, C. M., Fitch, A., Ard, J. D., Li, Z., Richards, J., Butsch, W. S., Jouravskaya, I., et al. (2024) · Obesity · doi:10.1002/oby.24067 · Cited by 134 · see citing works
Gortan Cappellari, G., Guillet, C., Poggiogalle, E., Ballesteros Pomar, M. D., Batsis, J. A., Boirie, Y., Breton, I., Frara, S., Genton, L., Gepner, Y., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.02.018 · Cited by 113 · see citing works
Self-citationJohansson, K., Sundström, J., Marcus, C., Hemmingsson, E., & Neovius, M. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.83 · Cited by 87 · see citing works
Current pharmacotherapies for sarcopenia
Hardee, J. P., & Lynch, G. S. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1622093 · Cited by 86 · see citing works
Treatment of obesity in older persons—A systematic review
Haywood, C., & Sumithran, P. (2019) · Obesity Reviews · doi:10.1111/obr.12815 · Cited by 84 · see citing works
Tinsley, G. M., & Heymsfield, S. B. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae164 · Cited by 81 · see citing works
Bariatric Surgery Outcomes in Sarcopenic Obesity
Mastino, D., Robert, M., Betry, C., Laville, M., Gouillat, C., & Disse, E. (2016) · Obesity Surgery · doi:10.1007/s11695-016-2102-7 · Cited by 79 · see citing works
Kolotkin, R. L., Williams, V. S. L., Ervin, C. M., Williams, N., Meincke, H. H., Qin, S., Smith, L. V. H., & Fehnel, S. E. (2019) · Clinical Obesity · doi:10.1111/cob.12310 · Cited by 76 · see citing works
The prevalence of low muscle mass associated with obesity in the USA
Murdock, D. J., Wu, N., Grimsby, J. S., Calle, R. A., Donahue, S., Glass, D. J., Sleeman, M. W., & Sanchez, R. J. (2022) · Skeletal Muscle · doi:10.1186/s13395-022-00309-5 · Cited by 73 · see citing works
Ashtary-Larky, D., Bagheri, R., Abbasnezhad, A., Tinsley, G. M., Alipour, M., & Wong, A. (2020) · British Journal of Nutrition · doi:10.1017/s000711452000224x · Cited by 72 · see citing works
Exercise and physical performance in older adults with sarcopenic obesity: A systematic review
Ghiotto, L., Muollo, V., Tatangelo, T., Schena, F. F., & Rossi, A. P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.913953 · Cited by 69 · see citing works
Ritz, P., Sallé, A., Audran, M., & Rohmer, V. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.01.007 · Cited by 59 · see citing works
Rubino, D., Bjorner, J. B., Rathor, N., Sharma, A. M., von Huth Smith, L., Wharton, S., Wadden, T., Zeuthen, N., & Kolotkin, R. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15620 · Cited by 56 · see citing works
Haghighat, N., Kazemi, A., Asbaghi, O., Jafarian, F., Moeinvaziri, N., Hosseini, B., & Amini, M. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2020.10.001 · Cited by 47 · see citing works
Advances and challenges in geroscience research: An update
Yabluchanskiy, A., Ungvari, Z. I., Csiszár, A., & Tarantini, S. (2018) · Physiology International · doi:10.1556/2060.105.2018.4.32 · Cited by 42 · see citing works
Du, Y., Xu, T., Yin, Z., Espinoza, S., Xie, Y., Gentry, C., Tian, Q., Zhao, L.-J., Shen, H., Luo, Z., et al. (2022) · BMC Public Health · doi:10.1186/s12889-022-13288-5 · Cited by 39 · see citing works
Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders
Giorgi, R. D., Ghenciulescu, A., Yotter, C. N., Taquet, M., & Koychev, I. G. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-335593 · Cited by 39 · see citing works
Reiter, L., Bauer, S., Traxler, M., Schoufour, J. D., Weijs, P. J. M., Cruz-Jentoft, A., Topinková, E., & Eglseer, D. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00509-0 · Cited by 35 · see citing works
Yabe, D., Yamada, Y., Kaku, K., Nishida, T., Sato, T., & Seino, Y. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13773 · Cited by 23 · see citing works
Sterczala, A. J., Pierce, J. R., Barnes, B. R., Urso, M. L., Matheny, R. W., Scofield, D. E., Flanagan, S. D., Maresh, C. M., Zambraski, E. J., Kraemer, W. J., et al. (2022) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00592.2021 · Cited by 11 · see citing works
Gadowski, A. M., Curtis, A. J., Heritier, S. R., Zoungas, S., & Owen, A. J. (2021) · Human Nutrition & Metabolism · doi:10.1016/j.hnm.2021.200127 · Cited by 8 · see citing works
Efficacy of antiobesity medications for weight reduction in older adults: a systematic review
Chen, A. S., Hajduk, A. M., Grimshaw, A. A., Fried, T. R., Jastreboff, A. M., & Lipska, K. J. (2024) · Obesity · doi:10.1002/oby.24160 · Cited by 3 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 3
- [5]5. Batsis JA, Barre LK, Mackenzie TA, Pratt SI, Lopez-Jimenez F, Bartels SJ. Variation in the prevalence of sarcopenia and sarcopenic obesity in older adults associated with different research definitions: dual-energy X-ray absorptiometry data from the National Health and Nutrition Examination Survey 1999-2004. J Am Geriatr Soc 2013;61:974-980
- [9]9. Volpi E, Nazemi R, Fujita S. Muscle tissue changes with aging. Curr Opin Clin Nutr Metab Care 2004;7:405-410
- [40]40. Kushner R, Aronne L, Stefanski A, et al. Tirzepatide-induced weight loss is associated with body composition improvements across age groups. Obesity (Silver Spring) 2022;30:49
Cited by
Sorted by citations
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123 · see citing works
Yamanouchi, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010027 · Cited by 27 · see citing works
GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations
Scheen, A. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101708 · Cited by 20 · see citing works
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13 · see citing works
Orioli, L., Thissen, J.-P., & Loumaye, A. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.106547 · Cited by 9 · see citing works
Lempesis, I. G., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100463 · Cited by 8 · see citing works
GLP-1 and GIP: Magic bullet for musculoskeletal diseases?
Fang, Q., Gan, L., Liu, P., Ding, P., & Gao, Y. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.046 · Cited by 5 · see citing works
Ezenekwe, L., & Newberry, C. A. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.70074 · Cited by 3 · see citing works
Zhang, Z., Yi, R., Xiong, S., Zhang, Y., Cao, X., Zhen, W., Yang, Y., & Gong, N. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113055 · Cited by 3 · see citing works
Салухов, В. В., Борисович, Ш. С., & Petrankov, K. V. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-467 · Cited by 2 · see citing works
Yang, Q., Wang, Y., Gao, G., Li, H., Gao, Y., & He, J. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02133-z · Cited by 2 · see citing works
Yang, W., Hao, C., Wang, N., Xie, J., Zhou, B., Yang, Z., Zheng, A., Wei, J., Li, C., Xie, C., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2661854 · Cited by 2 · see citing works
Preventive Strategies to Reduce Sarcopenia Risk During GLP-1-Based Anti-Obesity Therapy
Belančić, A., Skroče, K., Gkrinia, E. M. M., Glavić, M. M., & Kwok, M. K. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15155870 · Cited by 2 · see citing works
Godziuk, K., Vieira, F. T., Forhan, M. A., Batsis, J. A., Donini, L. M., González, M. C., Siervo, M., & Prado, C. M. M. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.11.143 · Cited by 1 · see citing works
Self-citationSanchis‐Gomar, F., Neeland, I. J., Ruiz‐Lozano, P., Alnahar, O., & Rodríguez, F. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02334-4 · Cited by 1 · see citing works
Kway, Y. M., Raisi‐Estabragh, Z., Vavilis, G., Antoniades, C. A., Petersen, S. E., Nichols, T. E., Raman, B., Zhang, Q., & Neubauer, S. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag702 · Cited by 1 · see citing works
Master, H., Petersen, M. A., Bynum, L. G., Donnelly, R. J., & Batsis, J. A. (2026) · Current Geriatrics Reports · doi:10.1007/s13670-026-00462-5
Self-citationSong, H., Yan, L., Zhao, W., & Yu, Z. (2026) · npj Science of Food · doi:10.1038/s41538-026-00887-4
Sun, J., Wen, D., Lin, Y., Tianshuo, Y., Deyu, S., & Yin, X. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124508
Godziuk, K., Tilley, S., LaValley, M. P., Kiel, D. P., Nevitt, M. C., Lewis, C. E., Jc, T., & Neogi, T. (2026) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2026.07.007
Interorgan Crosstalk in MASLD: A Narrative Review
Lonardo, A., & Weiskirchen, R. (2026) · Biomedicines · doi:10.3390/biomedicines14091949 · Cited by 1 · see citing works
Metabolic Determinants of Weight-Loss Quality During and After Incretin-Based Therapies in Obesity
Luna, M., Rodrigues, B., & Ramalho, A. (2026) · Clinical Nutrition Open Science · doi:10.1016/j.nutos.2026.100711
Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity
Mollero, E. L. M., Dozzani, I., Biamonte, E., Bendotti, G., Marzullo, P., Aimaretti, G., & Gallo, M. (2026) · Nutrients · doi:10.3390/nu18162654
Ming, Q., & Li, Z. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1914155
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395
Wolszczak, A., Martynowska, W., Hajt, M., Misiaszek, D., Graczyk, A., Ciecierski, P., Grabowska, N., Motor, J., & Turzyńska, P. P. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5940
Adhikari, S., Carlyle, B. C., & de Wet, H. (2026) · The Journal of Precision Medicine Health and Disease · doi:10.1016/j.premed.2026.100057
Li, Z., Wang, J., Han, X., Tian, Y., Zhu, X., Li, Y., Liu, L., & Xu, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1936660
Paccou, J., Rolvien, T., Hauser, B., Sølling, A. S., Anastasilakis, A. D., & Lems, W. F. (2026) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x261460301
Sarcopenic Obesity and Falls in Older Adults: A Narrative Review
Yan, W., & Zhou, B. (2026) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2026.1410006
Nutritional Impairment and Muscle Health in MASLD: The Potential Role of Eating Behaviors
Armașu, I., Ungureanu, M.-C., Gheorghe, L., Botnariu, G., Florescu, A.-F., Matei, A., Jari, I., Rusu, R. E., Cojocaru, E., Vasiliu, I., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15218306
ZAFER, E., Çekiç, D., Genç, A. B., & Yaylacı, S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15218377
- Authors
- Chen, A. S., & Batsis, J. A.
- Affiliations
- Yale University (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Batsis, John A.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2025-07-11
- Volume
- 74
- Issue
- 12
- Pages
- 2179-2190
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W4412203922
- Semantic Scholar
- 1583c9c33aed801c967f43e13c89a46e1d1ef35c
- Cited by
- 32
- References
- 63
- Citations by year
- 2026: 22 · 2025: 10
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30DK056350-23, R01 AG071663, T32 AG01914)
- Topics
- Health Sciences › Medicine › Physiology › Nutrition and Health in Aging
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- sarcopenic obesity, sarcopenia, older adults, GLP-1 receptor agonists, GIP/GLP-1 receptor agonist, liraglutide, semaglutide, tirzepatide, muscle mass loss, weight loss, geroscience, aging, adverse events
- MeSH terms
- Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Glucagon-Like Peptides, Humans, Obesity, Incretins, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
